Tzield, approved by the FDA in 2022, is now available as an option for patients with Stage-2 Type 1 diabetes.
Dr. Garg joined the faculty at the Barbara Davis center in 1992 and holds two endowed chairs at the University of Colorado Anschutz Medical Campus. He heads one of the top teams world-wide investigating insulin analogs and novel methods of insulin delivery. He has been the editor-in-chief of the Diabetes Technology and Therapeutics Journal since 2006 and has been the director of the annual ATDC Diabetes Conference in Keystone, Colorado since 2005. He was awarded the ATTD Lilly Insulin Centennial Award for 2023 in Berlin, Germany. Congratulation Dr. Garg!
Dr. Rachel Friedman was awarded a grant from the Helmsley Charitable Trust in 2023 for her work mononuclear phagocyte populations in T1D islets. Dr. Friedman's research interests include how T cells interact with antigen presenting cells at the disease site can result in T cell activation or tolerance. Her main aim is to understand how the immune system dynamically regulates immune responses though cellule responses and environmental cues and develop therapeutic interventions to disrupt pathogenic cellular interactions that promote autoimmunity.
Congratulations to Dr. Maki Nakayama, the recipient of the 2022 George Eisenbarth Memorial Lecture at the 14th annual (Network for Pancreatic Organ Donors with Diabetes (nPOD) meeting. Dr. Nakayama was honored for her outstanding research program investigating insulin-specific T cell populations present in the islets of individuals with type 1 diabetes.
For more information on screening and onset of T1D, see Ask the Experts, a program run by the BDC.
For more information on screening and onset of T1D, see Ask the Experts, a program run by the BDC.
